Moleculin Biotech regains compliance with Nasdaq bid price rule

Moleculin Biotech, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing of its common stock.

Rhea-AI Filing Summary

Moleculin Biotech, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing of its common stock. The company had previously been notified on June 27, 2025 that its shares failed to meet the Nasdaq Listing Rule 5550(a)(2) requirement after trading below $1.00 per share for 30 consecutive business days.

Nasdaq’s Listing Qualifications Staff informed Moleculin on December 15, 2025 that the company is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 10 consecutive business days from December 1, 2025 through December 12, 2025. Nasdaq indicated that the company is now in compliance with the bid price rule and that the matter is closed.

Positive

• Nasdaq confirms bid-price compliance restored: Moleculin’s common stock met the $1.00 minimum bid requirement for 10 consecutive business days, and Nasdaq has closed the prior deficiency matter.

Negative

• None.

Insights

Capital markets and listing compliance analyst

Nasdaq confirms Moleculin has cured its prior minimum bid price deficiency.

Moleculin Biotech previously received a deficiency notice on June 27, 2025 after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). That notice signaled the stock no longer met Nasdaq Capital Market’s continued listing standard for bid price.

On December 15, 2025, Nasdaq’s Listing Qualifications Staff notified the company that it had regained compliance. The closing bid price was at or above $1.00 per share for 10 consecutive business days from December 1, 2025 through December 12, 2025, satisfying Nasdaq’s cure requirement. The Staff stated the company is in compliance with the bid price rule and that the matter is closed, resolving the previously reported bid-price issue.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

What did Moleculin Biotech (MBRX) report in this 8-K?

Moleculin Biotech reported that Nasdaq’s Listing Qualifications Staff notified the company it has regained compliance with the minimum bid price requirement for its common stock and that the matter is closed.

Why was Moleculin Biotech (MBRX) previously out of compliance with Nasdaq rules?

On June 27, 2025, Moleculin Biotech received a deficiency letter because the bid price of its common stock had closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

How did Moleculin Biotech (MBRX) regain compliance with Nasdaq’s minimum bid price rule?

Nasdaq determined Moleculin regained compliance after the closing bid price of its common stock was at or above $1.00 per share for 10 consecutive business days from December 1, 2025 through December 12, 2025.

Which Nasdaq rule applies to Moleculin Biotech’s bid price issue?

The matter relates to Nasdaq Listing Rule 5550(a)(2), which sets the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.

Is the Nasdaq bid-price issue for Moleculin Biotech (MBRX) now resolved?

Yes. Nasdaq’s Listing Qualifications Staff stated that Moleculin Biotech is in compliance with the Bid Price Rule and that the bid-price deficiency matter is closed.

What exchange is Moleculin Biotech’s common stock listed on?

Moleculin Biotech’s common stock, par value $0.001 per share, trades on The Nasdaq Stock Market LLC under the symbol MBRX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/16/2025 - 05:20 PM Learn about SEC filing dates

false 0001659617 0001659617 2025-12-15 2025-12-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 15, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 8.01 Other Events.

As previously reported, on June 27, 2025, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

On December 15, 2025, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the 10 consecutive business days from December 1, 2025 through December 12, 2025. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date: December 16, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster
		Chief Financial Officer